New Evaluation and Material Transfer Agreement
Cytolytix enters evaluation agreement with Omios Biologics to combine oncolytic peptide technology with oncolytic virus platform.
Select text to share a quote on X · sign in to keep highlights & notes in your VAL notes
ValiRx plc (the "Company") (AIM: VAL), a life sciences company focusing on early-stage cancer therapeutics and women's health, is pleased to announce that its majority owned subsidiary, Cytolytix Ltd. ("Cytolytix") and Omios Biologics ("Omios"), a California based corporation, have entered into an Evaluation and Material Transfer agreement to evaluate the ability of Cytolytix's CLX001 oncolytic peptide technology to enhance activity of Omios's next-generation oncolytic virus immunotherapies (the "Agreement").
The Agreement focuses on incorporating Cytolytix's Oncolytic Peptide technology into the Omios next-generation Oncolytic Virus platform and is expected to take up to 12 months, for a nominal upfront payment. On conclusion of the evaluation, Omios has an option to enter into an Oncolytic Peptide License Agreement to continue using Cytolytix technology. This signifies an exciting new opportunity for ValiRx and Cytolytix to further expand its portfolio and commercialise its portfolio of innovative cancer therapeutics.
Mark Eccleston, CEO of ValiRx commented "We are pleased to announce this first Cytolytix commercial evaluation with Omios Bio and we see great synergy with their virus platform with a built-in biomarker for tumour targeting. We are very excited to work with Omios on the next generation of oncolytic virus leveraging Cytolytix's oncolytic peptide technology to enhance activity. Omios's innovative approach to enhancing their viruses' ability to selectively target and destroy cancer cells offers great synergy with our oncolytic peptide technology."
Aldo Pourceht, CEO of Omios Biologics commented "Our agreement with Cytolytix marks a significant strategic advancement for Omios. We look forward to evaluating how Cytolytix's oncolytic peptides can maximize the therapeutic impact of our next-generation VACV therapies. This collaboration is perfectly aligned with our core strategy: to build a leading oncolytic immunotherapy and tumor-targeted gene delivery platform, and most importantly, to rapidly advance our transformative cancer treatments into the clinic, for patients with challenging solid tumors."
| Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub | https://valirx.com/link/Ve9mNe |
| ValiRx plc Dr Mark Eccleston, CEO | Tel: +44 115 784 0026 www.valirx.com Mark.Eccleston@valirx.com |
| Cairn Financial Advisers LLP (Nominated Adviser) Liam Murray / Ludovico Lazzaretti | Tel: +44 (0) 20 7213 0880 |
| Shard Capital Partners LLP (Sole Broker) Damon Heath | Tel: +44 (0) 20 7186 9000 |
| V Formation (Public Relations) Lucy Wharton - Senior PR Executive Sue Carr - Director | +44 (0) 115 787 0206 www.vformation.biz lucy@vformation.biz sue@vformation.biz |
Subscribe to our news alert service: https://valirx.com/s/f298d1
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.